Skip to content
HowShorted

Phathom Pharmaceuticals, Inc. short interest in 2021

In 2021, Phathom Pharmaceuticals, Inc.'s disclosed short interest ran from 1.97% of shares outstanding on 15 Jan 2021 to 14.04% on 31 Dec 2021, a change of +12.07 percentage points. The year's high was 14.04% on 31 Dec 2021 and its low 1.44% on 26 Feb 2021, averaging 4.92% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 36.67 days on 31 Dec 2021. Full history: Phathom Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Phathom Pharmaceuticals, Inc. in 2021

2021 in figures

Start of year
1.97% (15 Jan 2021)
End of year
14.04% (31 Dec 2021)
Change
+12.07 pp
High
14.04% (31 Dec 2021)
Low
1.44% (26 Feb 2021)
Average
4.92%
Highest days to cover
36.67 (31 Dec 2021)
SEC filings marked
9

Every report in 2021

Phathom Pharmaceuticals, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20211.97%5.12
29 Jan 20211.66%5.22
12 Feb 20211.63%6.80
26 Feb 20211.44%4.18
15 Mar 20211.89%6.90
31 Mar 20211.81%5.8310-K filed, results (8-K)
15 Apr 20211.93%7.13
30 Apr 20212.23%10.13
14 May 20213.11%10.1910-Q filed, results (8-K)
28 May 20213.19%10.35
15 Jun 20213.30%13.53
30 Jun 20213.94%6.87
15 Jul 20213.96%19.67
30 Jul 20214.15%18.94
13 Aug 20215.05%16.9510-Q filed, results (8-K)
31 Aug 20215.10%20.49
15 Sep 20214.45%18.94
30 Sep 20214.82%16.95
15 Oct 20215.65%25.00
29 Oct 202111.33%8.46results (8-K)
15 Nov 202112.06%17.5110-Q filed, results (8-K)
30 Nov 20219.51%16.50
15 Dec 20219.77%28.35
31 Dec 202114.04%36.67

See also: Phathom Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.